Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:associatedWith |
gptkb:Revatio
gptkb:Cialis |
| gptkbp:ATCCode |
G04BE08
|
| gptkbp:brand |
gptkb:tadalafil
|
| gptkbp:CASNumber |
171596-29-5
|
| gptkbp:chemicalFormula |
C22H19N3O4
|
| gptkbp:contraindication |
concurrent nitrate therapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adcirca
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:mechanismOfAction |
phosphodiesterase type 5 inhibitor
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
muscle pain dyspepsia flushing |
| gptkbp:usedFor |
pulmonary arterial hypertension
|
| gptkbp:bfsParent |
gptkb:tadalafil
gptkb:Cialis |
| gptkbp:bfsLayer |
6
|